Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF594 divergent transcript (ZNF594-DT) is a long non-coding RNA (lncRNA) gene found in humans, annotated with the official symbols ENSG00000261879 (Ensembl) and 100130950 (NCBI). It is classified as a non-coding RNA, meaning it is transcribed into RNA but does not encode a protein product[3][5][6]. There is no published evidence as of September 2025 that ZNF594-DT is a direct therapeutic target, biomarker, or has a defined protein-like mechanism of action. Its biological role remains unknown, although lncRNAs generally may act in the regulation of gene expression, chromatin modification, or other diverse cellular processes[5][6]. There are no known disease associations, safety concerns, or drugs that interact with this transcript at present. ZNF594-DT (ZNF594 divergent transcript) is a human long non-coding RNA with no established biological or disease roles, drug interactions, or function as a therapeutic or diagnostic target[5][6][3].
none (not known to be directly targeted by drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF594 divergent transcript (ZNF594-DT).